ENTA - Enanta Pharma stock falls after phase 2b study evaluating EDP-938 did not meet main goal

Enanta Pharmaceuticals (NASDAQ:ENTA) stock has lost 6.2% to $45.97 in Wednesday aftermarket trade, after the clinical-stage biotech said its phase 2b study evaluating its inhibitor EDP-938 in adults with respiratory syncytial virus (RSV) did not meet its main goal. The main goal, or primary endpoint, of the study was reduction in total symptom score with EDP-938 compared to a placebo. RSV is a common respiratory virus that usually causes mild, cold-like symptoms. Most people recover in a week or two, but RSV can be serious, especially for infants and older adults. ENTA said a statistically significant difference in the number of subjects achieving undetectable RSV RNA at the end of treatment at day 5 was observed with EDP-938 vs. placebo. EDP-938 was also safe and well-tolerated. ENTA said it continues to evaluate EDP-938 in ongoing and planned clinical studies in high-risk populations.

For further details see:

Enanta Pharma stock falls after phase 2b study evaluating EDP-938 did not meet main goal